Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10250MR)

This product GTTS-WQ10250MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10250MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12794MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ2915MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ2333MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ1554MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ8437MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ10161MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ7846MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ1818MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW